利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.036 秒)

    Method For Preparing Radioactive Film
    1.
    发明申请
    Method For Preparing Radioactive Film 审中-公开
    放射性膜制备方法

    公开(公告)号：US20080031811A1

    公开(公告)日：2008-02-07

    申请号：US11575170

    申请日：2005-09-12

    申请人： Jei-Man Ryu ,  Yu-Eun Kim ,  Seung-Kyoo Seong ,  Dong-Hyuk Shin ,  Byung-Ho Cho ,  Young-Jun Song ,  Kyung-Bae Park ,  Byung-Chul Shin

    发明人： Jei-Man Ryu ,  Yu-Eun Kim ,  Seung-Kyoo Seong ,  Dong-Hyuk Shin ,  Byung-Ho Cho ,  Young-Jun Song ,  Kyung-Bae Park ,  Byung-Chul Shin

    IPC分类号： A61K51/12 ,  A61M36/14

    CPC分类号： A61K51/1279 ,  C08J5/18 ,  C08J2375/04 ,  C08K3/16 ,  C08K3/28

    摘要： The present invention relates to a method for preparing a radioactive film for local radioactive treatment. More particularly, the present invention relates to a method for preparing a radioactive film comprising the steps of; dissolving 0.1˜14.5 weight % of a stable nuclide and 13˜32.5 weight % of a film-forming base for the total amount of a solvent in the solvent; applying a stable nuclide solution on a release paper by a coater and drying; and irradiating a stable nuclide film with neutrons in a nuclear reactor. A method for preparing a radioactive film according to the present invention provides a radioactive film having a uniform distribution of radionuclides and an even thickness. Therefore, the therapeutic efficacy of the radioactive film for selective treatment of a lesion may be maximized by attaching the radioactive film on a patient's skin or a mucous membrane and by direct radioactive radiation.

    摘要翻译： 本发明涉及一种用于局部放射性处理的放射性膜的制备方法。 更具体地，本发明涉及一种制备放射性膜的方法，包括以下步骤： 将0.1〜14.5重量％的稳定核素和13〜32.5重量％的成膜基质溶解在溶剂中的溶剂的总量; 通过涂布机将稳定的核素溶液施加在剥离纸上并干燥; 并在核反应堆中用中子照射稳定的核素膜。 根据本发明的制备放射性膜的方法提供了具有均匀分布的放射性核素的均匀厚度的放射性膜。 因此，通过将放射性膜附着在患者的皮肤或粘膜上以及通过直接的放射性辐射，用于选择性治疗病变的放射性膜的治疗功效可以最大化。

    A radiosotope-chitosan complex for treatment of prostate cancer
    2.
    发明申请
    A radiosotope-chitosan complex for treatment of prostate cancer 审中-公开
    一种用于治疗前列腺癌的放射性脱氧壳聚糖复合物

    公开(公告)号：US20060286032A1

    公开(公告)日：2006-12-21

    申请号：US10570295

    申请日：2004-09-08

    申请人： Jei-Man Ryu ,  Dong-Hyuk Shin ,  Seung-Kyoo Seong ,  Hee-Bog Yang ,  Eun-Jung Bae ,  Young-Jun Song ,  Kyung-Bae Park ,  Byung-Chul Shin

    发明人： Jei-Man Ryu ,  Dong-Hyuk Shin ,  Seung-Kyoo Seong ,  Hee-Bog Yang ,  Eun-Jung Bae ,  Young-Jun Song ,  Kyung-Bae Park ,  Byung-Chul Shin

    IPC分类号： A61K51/00 ,  C08B37/08

    CPC分类号： A61K51/06 ,  A61K51/1282

    摘要： Disclosed is a composition for treating prostate cancer. The composition for treating prostate cancer comprises as an effective ingredient a radioisotope-chitosan complex that includes a therapeutic radioisotope emitting beta radiation and chitosan. Also, the present invention discloses a kit for preparing the composition. When directly administered to a prostate cancer tissue, the radioisotope- chitosan complex is deposited in the applied target site while not leaking from the applied target site, and strongly inhibits the growth of prostate cancer cells while minimizing the side effects of conventional therapies, including urinary incontinence, urethral stricture and rectal bleeding. In addition, the radioisotope-chitosan complex may be used as an effective therapeutic agent for hormone-independent prostate cancer that is resistant to hormone therapy.

    摘要翻译： 公开了用于治疗前列腺癌的组合物。 用于治疗前列腺癌的组合物包括放射性同位素 - 壳聚糖复合物作为有效成分，其包括发射β辐射和壳聚糖的治疗性放射性同位素。 此外，本发明公开了一种用于制备组合物的试剂盒。 当直接施用于前列腺癌组织时，放射性同位素 - 壳聚糖复合物沉积在施用的靶位点，而不会从施用的靶位点泄漏，并强烈地抑制前列腺癌细胞的生长，同时最小化常规治疗的副作用，包括尿 尿失禁，尿道狭窄和直肠出血。 此外，放射性同位素 - 壳聚糖复合物可用作对激素治疗具有抗性的激素非依赖性前列腺癌的有效治疗剂。

    Oral Preparation Having Improved Bioavailability
    6.
    发明申请
    Oral Preparation Having Improved Bioavailability 审中-公开
    具有改善生物利用度的口服制剂

    公开(公告)号：US20070254930A1

    公开(公告)日：2007-11-01

    申请号：US11577469

    申请日：2005-11-22

    申请人： Jei Ryu ,  Soon Cho ,  Se Jung ,  Seung-Kyoo Seong ,  Eun Cho ,  Seok Ahn ,  Yun-Jung Kim

    发明人： Jei Ryu ,  Soon Cho ,  Se Jung ,  Seung-Kyoo Seong ,  Eun Cho ,  Seok Ahn ,  Yun-Jung Kim

    IPC分类号： A61K31/426 ,  A61P19/10 ,  C07D277/28

    CPC分类号： C07D277/24 ,  A61K9/143 ,  A61K31/426

    摘要： The present invention relates to an oral preparation of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxyl-benzamidine having improved bioavailability. More particularly, the present invention relates to an oral preparation comprising: N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salt thereof; and one or more carbonates selected from the group consisting of alkalimetal carbonate, alkalimetal bicarbonate and alkaline earth metal carbonate, and/or one or more disintegrants selected from the group consisting of sodium starch glycolate, carmellose calcium and croscarmellose sodium. The oral preparation according to the present invention inhibits gelation of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salt thereof in the early stage of release, which increases dissolution rate and remarkably raises bioavailability.

    摘要翻译： 本发明涉及具有改善的生物利用度的N-羟基-4- {5- [4-（5-异丙基-2-甲基-1,3-噻唑-4-基）苯氧基]戊氧基 - 苄脒的口服制剂。 更具体地说，本发明涉及包含N-羟基-4- {5- [4-（5-异丙基-2-甲基-1,3-噻唑-4-基）苯氧基]戊氧基} - 苄脒的口服制剂 或其药学上可接受的盐; 和一种或多种选自碳酸亚烷基碳酸盐，碱金属碳酸氢盐和碱土金属碳酸盐的碳酸盐，和/或选自淀粉羟乙酸钠，羧甲纤维素钙和交联羧甲基纤维素钠的一种或多种崩解剂。 根据本发明的口服制剂抑制N-羟基-4- {5- [4-（5-异丙基-2-甲基-1,3-噻唑-4-基）苯氧基]戊氧基} - 苄脒或药学上的凝胶化 在释放的早期阶段可接受的盐，其增加溶解速率并显着提高生物利用度。